Skip to main content
Clinical Trials/IRCT138902141096N2
IRCT138902141096N2
Completed
未知

Randomized clinical trial of the efficacy of oxytocin with propranol and oxytocin with placebo on the labor augmentation.

Vice Chancellor for research-Guilan University of Medical Sciences0 sites118 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Single spontaneous delivery.
Sponsor
Vice Chancellor for research-Guilan University of Medical Sciences
Enrollment
118
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Vice Chancellor for research-Guilan University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria included: Primiparous pregnant women with single fetus and cephalic presentation the top 37 weeks of pregnancy (According to reliable LMP or ultrasound the first trimester) with intact membrance And fetal heart rate between 120 to 160 beats per minute and estimated fetal weight by ultrasound examination or visitors between 2500 and 4000 g and in the active phase of labor had no failure to progress. Exclusion criteria: Multi\-parity, History of surgery on the uterus, malpresentation (non\-cephalic), Mismatch over maternal fetal pelvis , Fetal distress, including late deceleration (Gradually reducing the minimum and maximum heart rate after completing the contract with the minimum loss rate of 15 and may take over 15 seconds) or prolong deceleration (longs over two minutes and less than 10 minutes) , Suspected macrosomia (Estimated weight over 4000 g) ,polyhydroamnius , IUGR (Estimated fetal weight using ultrasound is lower than the tenth percentile) , Women whit systolic blood pressure 90 mmHg or less And with heart rate \<60 beats per minute and Women with a history of these diseases are also excluded: HTN ,Cardiac disease (Cardiac block,CHF , Right ventricular failure secondary to pulmonary hyper tension , Sinus bradycardia, Cardiogenic shock ,Significant aortic or mitral valve disease. And lung disease (Bronchial asthma or bronchospasm, severe chronic obstructive pulmonary disease, allergic rhinitis) Patients with kidney or liver dysfunction, diabetes, patients prone to hypoglycemia, myasthenia Gravis and Wolf \- Parkinson – White.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials